The hope but challenge for developing a vaccine that might control malaria

European Journal of Immunology

Volumn 39, Issue 4, 2009, Pages 939-943

  Good, Michael F ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Immunological memory; Malaria vaccines

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; ERYTHROCYTE MEMBRANE PROTEIN 1; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; PARASITE ANTIGEN;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CROSS REACTION; DOSE RESPONSE; DRUG EFFICACY; GENETIC POLYMORPHISM; HUMAN; MALARIA; MALARIA CONTROL; MEMORY CELL; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VACCINE PRODUCTION; ANIMAL; IMMUNOLOGY; MALARIA FALCIPARUM; METABOLISM; PARASITOLOGY; PHYSIOLOGY; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTIGENS, PROTOZOAN; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 65449147593     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200939390     Document Type: Article

References (41)

1. Kemp, D. J., Coppel, R. L., Cowman, A. F., Saint, R. B., Brown, G. V. and Anders, R. F., Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: Detection with antibodies from immune humans. Proc. Natl. Acad. Sci. USA 1983. 80: 3787-3791.
2. Ellis, J., Ozaki, L. S., Gwadz, R. W., Cochrane, A. H., Nussenzweig, V., Nussenzweig, R. S. and Godson, G. N., Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature 1983. 302: 536-538.
3. Dame, J. B., Williams, J. L., McCutchan, T. F., Weber, J. L., Wirtz, R. A., Hockmeyer, W. T., Maloy, W. L. et al., Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984. 225: 593-599.
4. Enea, V., Ellis, J., Zavala, F., Arnot, D. E., Asavanich, A., Masuda, A., Quakyi, I. and Nussenzweig, R. S., DNA cloning of Plasmodium falciparum circumsporozoite gene: Amino acid sequence of repetitive epitope. Science 1984. 225: 628-630.
5. Ballou, W. R., Hoffman, S. L., Sherwood, J. A., Hollingdale, M. R., Neva, F. A., Hockmeyer, W. T., Gordon, D. M. et al., Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987. 1: 1277-1281.
6. Herrington, D. A., Clyde, D. F., Losonsky, G., Cortesia, M., Murphy, J. R., Davis, J., Baqar, S. et al., Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987. 328: 257-259.
7. Graves, P. M. and Gelband, H., Vaccines for preventing malaria (SPf66). Cochrane Database Syst. Rev. 2006. Issue 2. Art. no.: CD005966. DOI: 10.1002/14651858.CD005966.
8. Stoute, J. A., Slaoui, M.,Heppner, D. G.,Momin, P., Kester, K. E., Desmons, P., Wellde, B. T. et al., A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 1997. 33: 86-91.
9. Bejon, P., Lusingu, J., Olotu, A., Leach, A., Lievens, M., Vekemans, J., Mshamu, S. et al., Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 2008. 359: 2521-2532.
10. Abdulla, S., Oberholzer, R., Juma, O., Kubhoja, S., Machera, F., Membi, C., Omari, S. et al., Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N. Engl. J. Med. 2008. 359: 2533-2544.
11. Bojang, K. A., Milligan, P. J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K. E., Ballou, W. R. et al., Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial. RTS, S Malaria Vaccine Trial Team. Lancet 2001. 358: 1927-1934.
12. Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Aide, P., Sigauque, B. et al., Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomised controlled trial. Lancet 2005. 366: 2012-2018.
13. Good, M. F., Pombo, D., Quakyi, I. A., Riley, E. M., Houghten, R. A., Menon, A., Alling, D. W. et al., Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc. Natl. Acad. Sci. USA 1988. 85: 1199-1203.
14. Zevering, Y., Khamboonruang, C. and Good, M. F., Natural amino acid polymorphisms of the circumsporozoite protein of Plasmodium falciparum abrogate specific human CD4+T cell responsiveness. Eur. J. Immunol. 1994. 24: 1418-1425.
15. Charoenvit, Y., Mellouk, S., Cole, C., Bechara, R., Leef, M. F., Sedegah, M., Yuan, L. F. et al., Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J. Immunol. 1991. 146: 1020-1025.
16. Charoenvit,Y.,Collins,W. E., Jones, T.R.,Millet, P.,Yuan, L.,Campbell, G. H., Beaudoin, R. L. et al., Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science 1991. 251: 668-671.
17. Collins, W. E. and Barnwell, J. W., A hopeful beginning for malaria vaccines. N. Engl. J. Med. 2008. 359: 2599-2601.
18. Hoffman, S. L., Oster, C. N., Plowe, C. V., Woollett, G. R., Beier, J. C., Chulay, J. D., Wirtz, R. A. et al., Naturally acquired antibodies to sporozoites do not prevent malaria: Vaccine development implications. Science 1987. 237: 639-642.
19. Trager, W. and Jensen, J. B., Human malaria parasites in continuous culture. Science 1976. 193: 673-675.
20. Collins,W. E. and Jeffery, G.M., A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: Development of parasitologic and clinical immunity following secondary infection. Am. J. Trop. Med. Hyg. 1999. 61: 20-35.
21. Wellde, B. T., Diggs, C. L. and Anderson, S., Immunization of Aotus trivirgatus against Plasmodium falciparum with irradiated blood forms. Bull. World Health Organ. 1979. 57: 153-157.
22. Siddiqui, W. A., An effective immunization of experimental monkeys against a human malaria parasite, Plasmodium falciparum. Science 1977. 197: 388-389.
23. Martin, L.M., Sauerwein, R.W., Bousema, T., Lanar, D. E. and Richie, T. L., Malaria vaccines in clinical development: Introduction and recombinant/subunit approaches, in: Myron M. L. (Ed.), New Generation Vaccines, 4th Edn., Marcel Dekker, Inc., NY, USA 2009.
24. Kennedy, M. C., Wang, J., Zhang, Y., Miles, A. P., Chitsaz, F., Saul, A., Long, C. A. et al., In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): Production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. 2002. 70: 6948-6960.
25. Genton, B., Betuela, I., Felger, I., Al-Yaman, F., Anders, R. F., Saul,A., Rare, L. et al., A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 2002. 185: 820-827.
26. Singh, S., Miura, K., Zhou, H., Muratova, O., Keegan, B., Miles, A., Martin, L. B. et al., Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): Protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect. Immun. 2006. 74: 4573-4580.
27. Wykes, M. N., Zhou, Y. H., Liu, X. Q. and Good, M. F., Plasmodium yoelii can ablate vaccine-induced long-term protection in mice. J. Immunol. 2005. 175: 2510-2516.
28. Patarroyo, M. E., Amador, R., Clavijo, P., Moreno, A., Guzman, F., Romero, P., Tascon, R. et al., A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988. 332: 158-161.
29. Nosten, F., Luxemburger, C., Kyle, D. E., Ballou, W. R., Wittes, J., Wah, E., Chongsuphajaisiddhi, T. et al., Randomised double-blind placebocontrolled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet 1996. 348: 701-707.
30. Hoffman, S. L., Goh, L. M., Luke, T. C., Schneider, I., Le, T. P., Doolan, D. L., Sacci, J. et al., Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 2002. 185: 1155-1164.
31. Luke, T. C. and Hoffman, S. L., Rationale and plans for developing a nonreplicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 2003. 206: 3803-3808.
32. Mueller, A. K., Labaied, M., Kappe, S. H. and Matuschewski, K., Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005. 433: 164-167.
33. van Schaijk, B. C. L., Janse, C. J., van Gemert, G.-J., van Dijk, M. R., Gego, A. et al., Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS ONE 2008. 3: E3549.
34. Good, M. F., Berzofsky, J. A. and Miller, L. H., The T cell response to the malaria circumsporozoite protein: An immunological approach to vaccine development. Ann. Rev. Immunol. 1988. 6: 663-688.
35. Pombo, D. J., Lawrence, G., Hirunpetcharat, C., Rzepczyk, C., Bryden, M., Cloonan, N., Anderson, K. et al., Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002. 24: 610-617.
36. Elliott, S. R., Kuns, R. D. and Good, M. F., Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect. Immun. 2005. 73: 2478-2485.
37. Pinzon-Charry, A. and Good, M. F., Malaria vaccines: The case for a wholeorganism approach. Expert Opin. Biol. Ther. 2008. 8: 441-448.
38. Sempértegui, F., Estrella, B., Moscoso, J., Piedrahita, L., Hernández, D., Gaybor, J., Naranjo, P. et al., Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 1994. 12: 337-342.
39. Regis, D. P., Dobaño, C., Quiñones-Olson, P., Liang, X., Graber, N. L., Stefaniak, M. E., Campo, J. J. et al., Transcriptionally active PCR for antigen identification and vaccine development: In vitro genome-wide screening and in vivo immunogenicity. Mol. Biochem. Parasitol. 2008. 158: 32-45.
40. Miller, L. H., Postscript, in: Targett, G. A. T. (Ed.), Malaria. Waiting for the Vaccine, Wiley, Chichester 1991, pp. 221-224.
41. Miller, L. H., Howard, R. J., Carter, R., Good, M. F., Nussenzweig, V., and Nussenzweig, R. S., Research toward malaria vaccines. Science 1986. 234: 1349-1356.